Borrow it
Coverart for item
The Resource Antibacterial agents : chemistry, mode of action, mechanisms of resistance, and clinical applications, Rosaleen J. Anderson ... [et al.]

Antibacterial agents : chemistry, mode of action, mechanisms of resistance, and clinical applications, Rosaleen J. Anderson ... [et al.]

Work
Publication
Extent
xiv, 363 p.
Contents
  • 1.1.2.
  • 3.1.2.
  • Synthesis
  • 3.1.3.
  • Bioavailability
  • 3.1.4.
  • Mode of action and selectivity
  • 3.1.5.
  • Bacterial resistance
  • 3.1.6.
  • Clinical applications
  • Structure
  • 3.1.7.
  • Adverse drug reactions
  • 3.1.8.
  • Drug interactions
  • 3.1.9.
  • Recent developments
  • References
  • 3.2.
  • Trimethoprim
  • Key points
  • 1.1.3.
  • 3.2.1.
  • Discovery
  • 3.2.2.
  • Synthesis
  • 3.2.3.
  • Bioavailability
  • 3.2.4.
  • Mode of action and selectivity
  • 3.2.5.
  • Bacterial resistance
  • Antibacterial targets
  • 3.2.6.
  • Clinical applications
  • 3.2.7.
  • Adverse drug reactions
  • 3.2.8.
  • Drug interactions
  • 3.2.9.
  • Recent developments
  • References
  • Questions
  • 1.1.4.
  • Section 4
  • Agents Targeting Protein Synthesis
  • 4.1.
  • Aminoglycoside antibiotics
  • Key points
  • 4.1.1.
  • Discovery
  • 4.1.2.
  • Synthesis
  • 4.1.3.
  • Bacterial detection and identification
  • Bioavailability
  • 4.1.4.
  • Mode of action and selectivity
  • 4.1.5.
  • Bacterial resistance
  • 4.1.6.
  • Clinical applications
  • 4.1.7.
  • Adverse drug reactions
  • 4.1.8.
  • 1.1.5.
  • Drug interactions
  • 4.1.9.
  • Recent developments
  • References
  • 4.2.
  • Macrolide antibiotics
  • Key points
  • 4.2.1.
  • Discovery
  • 4.2.2.
  • Other than its mode of action, what factors determine the antibacterial activity of a drug?
  • Synthesis
  • 4.2.3.
  • Bioavailability
  • 4.2.4.
  • Mode of action and selectivity
  • 4.2.5.
  • Bacterial resistance
  • 4.2.6.
  • Clinical applications
  • 4.2.7.
  • 1.1.6.
  • Adverse drug reactions
  • 4.2.8.
  • Drug interactions
  • 4.2.9.
  • Recent developments
  • References
  • 4.3.
  • Tetracycline antibiotics
  • Key points
  • 4.3.1.
  • Bacterial resistance
  • Discovery
  • 4.3.2.
  • Synthesis
  • 4.3.3.
  • Bioavailability
  • 4.3.4.
  • Mode of action and selectivity
  • 4.3.5.
  • Bacterial resistance
  • 4.3.6.
  • Machine generated contents note:
  • 1.1.7.
  • Clinical applications
  • 4.3.7.
  • Adverse drug reactions
  • 4.3.8.
  • Drug interactions
  • 4.3.9.
  • Recent developments
  • References
  • 4.4.
  • Chloramphenicol
  • `post-antibiotic age'?
  • Key points
  • 4.4.1.
  • Discovery
  • 4.4.2.
  • Synthesis
  • 4.4.3.
  • Bioavailability
  • 4.4.4.
  • Mode of action and selectivity
  • 4.4.5.
  • References
  • Bacterial resistance
  • 4.4.6.
  • Clinical applications
  • 4.4.7.
  • Adverse drug reactions
  • 4.4.8.
  • Drug interactions
  • 4.4.9.
  • Recent developments
  • References
  • Questions
  • 4.5.
  • Oxazolidinones
  • Key points
  • 4.5.1.
  • Discovery
  • 4.5.2.
  • Synthesis
  • 4.5.3.
  • Bioavailability
  • 4.5.4.
  • Section 2
  • Mode of action and selectivity
  • 4.5.5.
  • Bacterial resistance
  • 4.5.6.
  • Clinical applications
  • 4.5.7.
  • Adverse drug reactions
  • 4.5.8.
  • Drug interactions
  • 4.5.9.
  • Agents Targeting DNA
  • Recent developments
  • References
  • Questions
  • Section 5
  • Agents Targeting Cell-Wall Synthesis
  • 5.1.
  • β-Lactam antibiotics
  • Key points
  • 5.1.1.
  • Discovery
  • 2.1.
  • 5.1.2.
  • Synthesis
  • 5.1.3.
  • Bioavailability
  • 5.1.4.
  • Mode of action and selectivity
  • 5.1.5.
  • Bacterial resistance
  • 5.1.6.
  • Clinical applications
  • Quinolone antibacterial agents
  • 5.1.7.
  • Adverse drug reactions
  • 5.1.8.
  • Drug interactions
  • 5.1.9.
  • Recent developments
  • References
  • 5.2.
  • Glycopeptide antibiotics
  • Key points
  • Key points
  • 5.2.1.
  • Discovery
  • 5.2.2.
  • Synthesis
  • 5.2.3.
  • Bioavailability
  • 5.2.4.
  • Mode of action and selectivity
  • 5.2.5.
  • Bacterial resistance
  • 2.1.1.
  • 5.2.6.
  • Clinical applications
  • 5.2.7.
  • Adverse drug reactions
  • 5.2.8.
  • Drug interactions
  • 5.2.9.
  • Recent developments
  • References
  • 5.3.
  • Section 1
  • Discovery
  • Cycloserine
  • Key points
  • 5.3.1.
  • Discovery
  • 5.3.2.
  • Synthesis
  • 5.3.3.
  • Bioavailability
  • 5.3.4.
  • Mode of action and selectivity
  • 2.1.2.
  • 5.3.5.
  • Bacterial resistance
  • 5.3.6.
  • Clinical applications
  • 5.3.7.
  • Adverse drug reactions
  • 5.3.8.
  • Drug interactions
  • 5.3.9.
  • Recent developments
  • Synthesis
  • References
  • 5.4.
  • Isoniazid
  • Key points
  • 5.4.1.
  • Discovery
  • 5.4.2.
  • Synthesis
  • 5.4.3.
  • Bioavailability
  • 2.1.3.
  • 5.4.4.
  • Mode of action and selectivity
  • 5.4.5.
  • Bacterial resistance
  • 5.4.6.
  • Clinical applications
  • 5.4.7.
  • Adverse drug reactions
  • 5.4.8.
  • Drug interactions
  • Bioavailability
  • 5.4.9.
  • Recent developments
  • References
  • 5.5.
  • Daptomycin
  • Key points
  • 5.5.1.
  • Discovery
  • 5.5.2.
  • Synthesis
  • 2.1.4.
  • 5.5.3.
  • Bioavailability
  • 5.5.4.
  • Mode of action and selectivity
  • 5.5.5.
  • Bacterial resistance
  • 5.5.6.
  • Clinical applications
  • 5.5.7.
  • Adverse drug reactions
  • Mode of action and selectivity
  • 5.5.8.
  • Drug interactions
  • 5.5.9.
  • Recent developments
  • References
  • Questions
  • 2.1.5.
  • Bacterial resistance
  • 2.1.6.
  • Introduction to Microorganisms and Antibacterial Chemotherapy
  • Clinical applications
  • 2.1.7.
  • Adverse drug reactions
  • 2.1.8.
  • Drug interactions
  • 2.1.9.
  • Recent developments
  • References
  • 2.2.
  • Rifamycin antibacterial agents
  • 1.1.
  • Key points
  • 2.2.1.
  • Discovery
  • 2.2.2.
  • Synthesis
  • 2.2.3.
  • Bioavailability
  • 2.2.4.
  • Mode of action and selectivity
  • 2.2.5.
  • Microorganisms
  • Bacterial resistance
  • 2.2.6.
  • Clinical applications
  • 2.2.7.
  • Adverse drug reactions
  • 2.2.8.
  • Drug interactions
  • 2.2.9.
  • Recent developments
  • References
  • Key points
  • 2.3.
  • Nitroimidazole antibacterial agents
  • Key points
  • 2.3.1.
  • Discovery
  • 2.3.2.
  • Synthesis
  • 2.3.3.
  • Bioavailability
  • 2.3.4.
  • 1.1.1.
  • Mode of action and selectivity
  • 2.3.5.
  • Mechanisms of resistance
  • 2.3.6.
  • Clinical applications
  • 2.3.7.
  • Adverse drug reactions
  • 2.3.8.
  • Drug interactions
  • 2.3.9.
  • Classification
  • Recent developments
  • References
  • Questions
  • Section 3
  • Agents Targeting Metabolic Processes
  • 3.1.
  • Sulfonamide antibacterial agents
  • Key points
  • 3.1.1.
  • Discovery
Isbn
9780470972458
Instance
Label
Antibacterial agents : chemistry, mode of action, mechanisms of resistance, and clinical applications
Title
Antibacterial agents
Title remainder
chemistry, mode of action, mechanisms of resistance, and clinical applications
Statement of responsibility
Rosaleen J. Anderson ... [et al.]
Contributor
Subject
Language
eng
Cataloging source
DLC
Dewey number
615.7/922
Illustrations
illustrations
Index
index present
Literary form
non fiction
Nature of contents
bibliography
NLM call number
QV 350
http://library.link/vocab/relatedWorkOrContributorName
Anderson, Rosaleen J
http://library.link/vocab/subjectName
Anti-Bacterial Agents
Label
Antibacterial agents : chemistry, mode of action, mechanisms of resistance, and clinical applications, Rosaleen J. Anderson ... [et al.]
Instantiates
Publication
Bibliography note
Includes bibliographical references and index
Contents
  • 1.1.2.
  • 3.1.2.
  • Synthesis
  • 3.1.3.
  • Bioavailability
  • 3.1.4.
  • Mode of action and selectivity
  • 3.1.5.
  • Bacterial resistance
  • 3.1.6.
  • Clinical applications
  • Structure
  • 3.1.7.
  • Adverse drug reactions
  • 3.1.8.
  • Drug interactions
  • 3.1.9.
  • Recent developments
  • References
  • 3.2.
  • Trimethoprim
  • Key points
  • 1.1.3.
  • 3.2.1.
  • Discovery
  • 3.2.2.
  • Synthesis
  • 3.2.3.
  • Bioavailability
  • 3.2.4.
  • Mode of action and selectivity
  • 3.2.5.
  • Bacterial resistance
  • Antibacterial targets
  • 3.2.6.
  • Clinical applications
  • 3.2.7.
  • Adverse drug reactions
  • 3.2.8.
  • Drug interactions
  • 3.2.9.
  • Recent developments
  • References
  • Questions
  • 1.1.4.
  • Section 4
  • Agents Targeting Protein Synthesis
  • 4.1.
  • Aminoglycoside antibiotics
  • Key points
  • 4.1.1.
  • Discovery
  • 4.1.2.
  • Synthesis
  • 4.1.3.
  • Bacterial detection and identification
  • Bioavailability
  • 4.1.4.
  • Mode of action and selectivity
  • 4.1.5.
  • Bacterial resistance
  • 4.1.6.
  • Clinical applications
  • 4.1.7.
  • Adverse drug reactions
  • 4.1.8.
  • 1.1.5.
  • Drug interactions
  • 4.1.9.
  • Recent developments
  • References
  • 4.2.
  • Macrolide antibiotics
  • Key points
  • 4.2.1.
  • Discovery
  • 4.2.2.
  • Other than its mode of action, what factors determine the antibacterial activity of a drug?
  • Synthesis
  • 4.2.3.
  • Bioavailability
  • 4.2.4.
  • Mode of action and selectivity
  • 4.2.5.
  • Bacterial resistance
  • 4.2.6.
  • Clinical applications
  • 4.2.7.
  • 1.1.6.
  • Adverse drug reactions
  • 4.2.8.
  • Drug interactions
  • 4.2.9.
  • Recent developments
  • References
  • 4.3.
  • Tetracycline antibiotics
  • Key points
  • 4.3.1.
  • Bacterial resistance
  • Discovery
  • 4.3.2.
  • Synthesis
  • 4.3.3.
  • Bioavailability
  • 4.3.4.
  • Mode of action and selectivity
  • 4.3.5.
  • Bacterial resistance
  • 4.3.6.
  • Machine generated contents note:
  • 1.1.7.
  • Clinical applications
  • 4.3.7.
  • Adverse drug reactions
  • 4.3.8.
  • Drug interactions
  • 4.3.9.
  • Recent developments
  • References
  • 4.4.
  • Chloramphenicol
  • `post-antibiotic age'?
  • Key points
  • 4.4.1.
  • Discovery
  • 4.4.2.
  • Synthesis
  • 4.4.3.
  • Bioavailability
  • 4.4.4.
  • Mode of action and selectivity
  • 4.4.5.
  • References
  • Bacterial resistance
  • 4.4.6.
  • Clinical applications
  • 4.4.7.
  • Adverse drug reactions
  • 4.4.8.
  • Drug interactions
  • 4.4.9.
  • Recent developments
  • References
  • Questions
  • 4.5.
  • Oxazolidinones
  • Key points
  • 4.5.1.
  • Discovery
  • 4.5.2.
  • Synthesis
  • 4.5.3.
  • Bioavailability
  • 4.5.4.
  • Section 2
  • Mode of action and selectivity
  • 4.5.5.
  • Bacterial resistance
  • 4.5.6.
  • Clinical applications
  • 4.5.7.
  • Adverse drug reactions
  • 4.5.8.
  • Drug interactions
  • 4.5.9.
  • Agents Targeting DNA
  • Recent developments
  • References
  • Questions
  • Section 5
  • Agents Targeting Cell-Wall Synthesis
  • 5.1.
  • β-Lactam antibiotics
  • Key points
  • 5.1.1.
  • Discovery
  • 2.1.
  • 5.1.2.
  • Synthesis
  • 5.1.3.
  • Bioavailability
  • 5.1.4.
  • Mode of action and selectivity
  • 5.1.5.
  • Bacterial resistance
  • 5.1.6.
  • Clinical applications
  • Quinolone antibacterial agents
  • 5.1.7.
  • Adverse drug reactions
  • 5.1.8.
  • Drug interactions
  • 5.1.9.
  • Recent developments
  • References
  • 5.2.
  • Glycopeptide antibiotics
  • Key points
  • Key points
  • 5.2.1.
  • Discovery
  • 5.2.2.
  • Synthesis
  • 5.2.3.
  • Bioavailability
  • 5.2.4.
  • Mode of action and selectivity
  • 5.2.5.
  • Bacterial resistance
  • 2.1.1.
  • 5.2.6.
  • Clinical applications
  • 5.2.7.
  • Adverse drug reactions
  • 5.2.8.
  • Drug interactions
  • 5.2.9.
  • Recent developments
  • References
  • 5.3.
  • Section 1
  • Discovery
  • Cycloserine
  • Key points
  • 5.3.1.
  • Discovery
  • 5.3.2.
  • Synthesis
  • 5.3.3.
  • Bioavailability
  • 5.3.4.
  • Mode of action and selectivity
  • 2.1.2.
  • 5.3.5.
  • Bacterial resistance
  • 5.3.6.
  • Clinical applications
  • 5.3.7.
  • Adverse drug reactions
  • 5.3.8.
  • Drug interactions
  • 5.3.9.
  • Recent developments
  • Synthesis
  • References
  • 5.4.
  • Isoniazid
  • Key points
  • 5.4.1.
  • Discovery
  • 5.4.2.
  • Synthesis
  • 5.4.3.
  • Bioavailability
  • 2.1.3.
  • 5.4.4.
  • Mode of action and selectivity
  • 5.4.5.
  • Bacterial resistance
  • 5.4.6.
  • Clinical applications
  • 5.4.7.
  • Adverse drug reactions
  • 5.4.8.
  • Drug interactions
  • Bioavailability
  • 5.4.9.
  • Recent developments
  • References
  • 5.5.
  • Daptomycin
  • Key points
  • 5.5.1.
  • Discovery
  • 5.5.2.
  • Synthesis
  • 2.1.4.
  • 5.5.3.
  • Bioavailability
  • 5.5.4.
  • Mode of action and selectivity
  • 5.5.5.
  • Bacterial resistance
  • 5.5.6.
  • Clinical applications
  • 5.5.7.
  • Adverse drug reactions
  • Mode of action and selectivity
  • 5.5.8.
  • Drug interactions
  • 5.5.9.
  • Recent developments
  • References
  • Questions
  • 2.1.5.
  • Bacterial resistance
  • 2.1.6.
  • Introduction to Microorganisms and Antibacterial Chemotherapy
  • Clinical applications
  • 2.1.7.
  • Adverse drug reactions
  • 2.1.8.
  • Drug interactions
  • 2.1.9.
  • Recent developments
  • References
  • 2.2.
  • Rifamycin antibacterial agents
  • 1.1.
  • Key points
  • 2.2.1.
  • Discovery
  • 2.2.2.
  • Synthesis
  • 2.2.3.
  • Bioavailability
  • 2.2.4.
  • Mode of action and selectivity
  • 2.2.5.
  • Microorganisms
  • Bacterial resistance
  • 2.2.6.
  • Clinical applications
  • 2.2.7.
  • Adverse drug reactions
  • 2.2.8.
  • Drug interactions
  • 2.2.9.
  • Recent developments
  • References
  • Key points
  • 2.3.
  • Nitroimidazole antibacterial agents
  • Key points
  • 2.3.1.
  • Discovery
  • 2.3.2.
  • Synthesis
  • 2.3.3.
  • Bioavailability
  • 2.3.4.
  • 1.1.1.
  • Mode of action and selectivity
  • 2.3.5.
  • Mechanisms of resistance
  • 2.3.6.
  • Clinical applications
  • 2.3.7.
  • Adverse drug reactions
  • 2.3.8.
  • Drug interactions
  • 2.3.9.
  • Classification
  • Recent developments
  • References
  • Questions
  • Section 3
  • Agents Targeting Metabolic Processes
  • 3.1.
  • Sulfonamide antibacterial agents
  • Key points
  • 3.1.1.
  • Discovery
Dimensions
25 cm.
Extent
xiv, 363 p.
Isbn
9780470972458
Isbn Type
(pbk.)
Lccn
2012006648
Other physical details
ill. (chiefly col.)
System control number
  • (CaMWU)u2764917-01umb_inst
  • 2611090
  • (Sirsi) i9780470972441
  • (OCoLC)775419593
Label
Antibacterial agents : chemistry, mode of action, mechanisms of resistance, and clinical applications, Rosaleen J. Anderson ... [et al.]
Publication
Bibliography note
Includes bibliographical references and index
Contents
  • 1.1.2.
  • 3.1.2.
  • Synthesis
  • 3.1.3.
  • Bioavailability
  • 3.1.4.
  • Mode of action and selectivity
  • 3.1.5.
  • Bacterial resistance
  • 3.1.6.
  • Clinical applications
  • Structure
  • 3.1.7.
  • Adverse drug reactions
  • 3.1.8.
  • Drug interactions
  • 3.1.9.
  • Recent developments
  • References
  • 3.2.
  • Trimethoprim
  • Key points
  • 1.1.3.
  • 3.2.1.
  • Discovery
  • 3.2.2.
  • Synthesis
  • 3.2.3.
  • Bioavailability
  • 3.2.4.
  • Mode of action and selectivity
  • 3.2.5.
  • Bacterial resistance
  • Antibacterial targets
  • 3.2.6.
  • Clinical applications
  • 3.2.7.
  • Adverse drug reactions
  • 3.2.8.
  • Drug interactions
  • 3.2.9.
  • Recent developments
  • References
  • Questions
  • 1.1.4.
  • Section 4
  • Agents Targeting Protein Synthesis
  • 4.1.
  • Aminoglycoside antibiotics
  • Key points
  • 4.1.1.
  • Discovery
  • 4.1.2.
  • Synthesis
  • 4.1.3.
  • Bacterial detection and identification
  • Bioavailability
  • 4.1.4.
  • Mode of action and selectivity
  • 4.1.5.
  • Bacterial resistance
  • 4.1.6.
  • Clinical applications
  • 4.1.7.
  • Adverse drug reactions
  • 4.1.8.
  • 1.1.5.
  • Drug interactions
  • 4.1.9.
  • Recent developments
  • References
  • 4.2.
  • Macrolide antibiotics
  • Key points
  • 4.2.1.
  • Discovery
  • 4.2.2.
  • Other than its mode of action, what factors determine the antibacterial activity of a drug?
  • Synthesis
  • 4.2.3.
  • Bioavailability
  • 4.2.4.
  • Mode of action and selectivity
  • 4.2.5.
  • Bacterial resistance
  • 4.2.6.
  • Clinical applications
  • 4.2.7.
  • 1.1.6.
  • Adverse drug reactions
  • 4.2.8.
  • Drug interactions
  • 4.2.9.
  • Recent developments
  • References
  • 4.3.
  • Tetracycline antibiotics
  • Key points
  • 4.3.1.
  • Bacterial resistance
  • Discovery
  • 4.3.2.
  • Synthesis
  • 4.3.3.
  • Bioavailability
  • 4.3.4.
  • Mode of action and selectivity
  • 4.3.5.
  • Bacterial resistance
  • 4.3.6.
  • Machine generated contents note:
  • 1.1.7.
  • Clinical applications
  • 4.3.7.
  • Adverse drug reactions
  • 4.3.8.
  • Drug interactions
  • 4.3.9.
  • Recent developments
  • References
  • 4.4.
  • Chloramphenicol
  • `post-antibiotic age'?
  • Key points
  • 4.4.1.
  • Discovery
  • 4.4.2.
  • Synthesis
  • 4.4.3.
  • Bioavailability
  • 4.4.4.
  • Mode of action and selectivity
  • 4.4.5.
  • References
  • Bacterial resistance
  • 4.4.6.
  • Clinical applications
  • 4.4.7.
  • Adverse drug reactions
  • 4.4.8.
  • Drug interactions
  • 4.4.9.
  • Recent developments
  • References
  • Questions
  • 4.5.
  • Oxazolidinones
  • Key points
  • 4.5.1.
  • Discovery
  • 4.5.2.
  • Synthesis
  • 4.5.3.
  • Bioavailability
  • 4.5.4.
  • Section 2
  • Mode of action and selectivity
  • 4.5.5.
  • Bacterial resistance
  • 4.5.6.
  • Clinical applications
  • 4.5.7.
  • Adverse drug reactions
  • 4.5.8.
  • Drug interactions
  • 4.5.9.
  • Agents Targeting DNA
  • Recent developments
  • References
  • Questions
  • Section 5
  • Agents Targeting Cell-Wall Synthesis
  • 5.1.
  • β-Lactam antibiotics
  • Key points
  • 5.1.1.
  • Discovery
  • 2.1.
  • 5.1.2.
  • Synthesis
  • 5.1.3.
  • Bioavailability
  • 5.1.4.
  • Mode of action and selectivity
  • 5.1.5.
  • Bacterial resistance
  • 5.1.6.
  • Clinical applications
  • Quinolone antibacterial agents
  • 5.1.7.
  • Adverse drug reactions
  • 5.1.8.
  • Drug interactions
  • 5.1.9.
  • Recent developments
  • References
  • 5.2.
  • Glycopeptide antibiotics
  • Key points
  • Key points
  • 5.2.1.
  • Discovery
  • 5.2.2.
  • Synthesis
  • 5.2.3.
  • Bioavailability
  • 5.2.4.
  • Mode of action and selectivity
  • 5.2.5.
  • Bacterial resistance
  • 2.1.1.
  • 5.2.6.
  • Clinical applications
  • 5.2.7.
  • Adverse drug reactions
  • 5.2.8.
  • Drug interactions
  • 5.2.9.
  • Recent developments
  • References
  • 5.3.
  • Section 1
  • Discovery
  • Cycloserine
  • Key points
  • 5.3.1.
  • Discovery
  • 5.3.2.
  • Synthesis
  • 5.3.3.
  • Bioavailability
  • 5.3.4.
  • Mode of action and selectivity
  • 2.1.2.
  • 5.3.5.
  • Bacterial resistance
  • 5.3.6.
  • Clinical applications
  • 5.3.7.
  • Adverse drug reactions
  • 5.3.8.
  • Drug interactions
  • 5.3.9.
  • Recent developments
  • Synthesis
  • References
  • 5.4.
  • Isoniazid
  • Key points
  • 5.4.1.
  • Discovery
  • 5.4.2.
  • Synthesis
  • 5.4.3.
  • Bioavailability
  • 2.1.3.
  • 5.4.4.
  • Mode of action and selectivity
  • 5.4.5.
  • Bacterial resistance
  • 5.4.6.
  • Clinical applications
  • 5.4.7.
  • Adverse drug reactions
  • 5.4.8.
  • Drug interactions
  • Bioavailability
  • 5.4.9.
  • Recent developments
  • References
  • 5.5.
  • Daptomycin
  • Key points
  • 5.5.1.
  • Discovery
  • 5.5.2.
  • Synthesis
  • 2.1.4.
  • 5.5.3.
  • Bioavailability
  • 5.5.4.
  • Mode of action and selectivity
  • 5.5.5.
  • Bacterial resistance
  • 5.5.6.
  • Clinical applications
  • 5.5.7.
  • Adverse drug reactions
  • Mode of action and selectivity
  • 5.5.8.
  • Drug interactions
  • 5.5.9.
  • Recent developments
  • References
  • Questions
  • 2.1.5.
  • Bacterial resistance
  • 2.1.6.
  • Introduction to Microorganisms and Antibacterial Chemotherapy
  • Clinical applications
  • 2.1.7.
  • Adverse drug reactions
  • 2.1.8.
  • Drug interactions
  • 2.1.9.
  • Recent developments
  • References
  • 2.2.
  • Rifamycin antibacterial agents
  • 1.1.
  • Key points
  • 2.2.1.
  • Discovery
  • 2.2.2.
  • Synthesis
  • 2.2.3.
  • Bioavailability
  • 2.2.4.
  • Mode of action and selectivity
  • 2.2.5.
  • Microorganisms
  • Bacterial resistance
  • 2.2.6.
  • Clinical applications
  • 2.2.7.
  • Adverse drug reactions
  • 2.2.8.
  • Drug interactions
  • 2.2.9.
  • Recent developments
  • References
  • Key points
  • 2.3.
  • Nitroimidazole antibacterial agents
  • Key points
  • 2.3.1.
  • Discovery
  • 2.3.2.
  • Synthesis
  • 2.3.3.
  • Bioavailability
  • 2.3.4.
  • 1.1.1.
  • Mode of action and selectivity
  • 2.3.5.
  • Mechanisms of resistance
  • 2.3.6.
  • Clinical applications
  • 2.3.7.
  • Adverse drug reactions
  • 2.3.8.
  • Drug interactions
  • 2.3.9.
  • Classification
  • Recent developments
  • References
  • Questions
  • Section 3
  • Agents Targeting Metabolic Processes
  • 3.1.
  • Sulfonamide antibacterial agents
  • Key points
  • 3.1.1.
  • Discovery
Dimensions
25 cm.
Extent
xiv, 363 p.
Isbn
9780470972458
Isbn Type
(pbk.)
Lccn
2012006648
Other physical details
ill. (chiefly col.)
System control number
  • (CaMWU)u2764917-01umb_inst
  • 2611090
  • (Sirsi) i9780470972441
  • (OCoLC)775419593

Subject

Library Locations

  • Albert D. Cohen Management LibraryBorrow it
    181 Freedman Crescent, Winnipeg, MB, R3T 5V4, CA
    49.807878 -97.129961
  • Architecture/Fine Arts LibraryBorrow it
    84 Curry Place, Winnipeg, MB, CA
    49.807716 -97.136226
  • Archives and Special CollectionsBorrow it
    25 Chancellors Circle (Elizabeth Dafoe Library), Room 330, Winnipeg, MB, R3T 2N2, CA
    49.809961 -97.131878
  • Bibliothèque Alfred-Monnin (Université de Saint-Boniface)Borrow it
    200, avenue de la Cathédrale, Local 2110, Winnipeg, MB, R2H 0H7, CA
    49.888861 -97.119735
  • Bill Larson Library (Grace Hospital)Borrow it
    300 Booth Drive, G-227, Winnipeg, MB, R3J 3M7, CA
    49.882400 -97.276436
  • Carolyn Sifton - Helene Fuld Library (St. Boniface General Hospital)Borrow it
    409 Tache Avenue, Winnipeg, MB, R2H 2A6, CA
    49.883388 -97.126050
  • Concordia Hospital LibraryBorrow it
    1095 Concordia Avenue, Winnipeg, MB, R2K 3S8, CA
    49.913252 -97.064683
  • Donald W. Craik Engineering LibraryBorrow it
    75B Chancellors Circle (Engineering Building E3), Room 361, Winnipeg, MB, R3T 2N2, CA
    49.809053 -97.133292
  • E.K. Williams Law LibraryBorrow it
    224 Dysart Road, Winnipeg, MB, R3T 5V4, CA
    49.811829 -97.131017
  • Eckhardt-Gramatté Music LibraryBorrow it
    136 Dafoe Road (Taché Arts Complex), Room 257, Winnipeg, MB, R3T 2N2, CA
    49.807964 -97.132222
  • Elizabeth Dafoe LibraryBorrow it
    25 Chancellors Circle, Winnipeg, MB, R3T 2N2, CA
    49.809961 -97.131878
  • Fr. H. Drake Library (St. Paul's College)Borrow it
    70 Dysart Road, Winnipeg, MB, R3T 2M6, CA
    49.810605 -97.138184
  • J.W. Crane Memorial Library (Deer Lodge Centre)Borrow it
    2109 Portage Avenue, Winnipeg, MB, R3J 0L3, CA
    49.878000 -97.235520
  • Libraries Annex (not open to the public; please see web page for details)Borrow it
    25 Chancellors Circle (in the Elizabeth Dafoe Library), Winnipeg, MB, R3T 2N2, CA
    49.809961 -97.131878
  • Neil John Maclean Health Sciences LibraryBorrow it
    727 McDermot Avenue (Brodie Centre), 200 Level, Winnipeg, MB, R3E 3P5, CA
    49.903563 -97.160554
  • Sciences and Technology LibraryBorrow it
    186 Dysart Road, Winnipeg, MB, R3T 2M8, CA
    49.811526 -97.133257
  • Seven Oaks General Hospital LibraryBorrow it
    2300 McPhillips Street, Winnipeg, MB, R2V 3M3, CA
    49.955177 -97.148865
  • Sister St. Odilon Library (Misericordia Health Centre)Borrow it
    99 Cornish Avenue, Winnipeg, MB, R3C 1A2, CA
    49.879592 -97.160425
  • St. John's College LibraryBorrow it
    92 Dysart Road, Winnipeg, MB, R3T 2M5, CA
    49.811242 -97.137156
  • Victoria General Hospital LibraryBorrow it
    2340 Pembina Highway, Winnipeg, MB, R3T 2E8, CA
    49.806755 -97.152739
  • William R Newman Library (Agriculture)Borrow it
    66 Dafoe Road, Winnipeg, MB, R3T 2R3, CA
    49.806936 -97.135525

Library Links

Zepheira Logo
Structured data from the Bibframe namespace is licensed under the Creative Commons Attribution 4.0 International License by University of Manitoba Libraries. Additional terms may apply to data associated with third party namespaces.
Processing Feedback ...